Cargando…
Immunological network signatures of cancer progression and survival
BACKGROUND: The immune contribution to cancer progression is complex and difficult to characterize. For example in tumors, immune gene expression is detected from the combination of normal, tumor and immune cells in the tumor microenvironment. Profiling the immune component of tumors may facilitate...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094196/ https://www.ncbi.nlm.nih.gov/pubmed/21453479 http://dx.doi.org/10.1186/1755-8794-4-28 |
_version_ | 1782203514364100608 |
---|---|
author | Clancy, Trevor Pedicini, Marco Castiglione, Filippo Santoni, Daniele Nygaard, Vegard Lavelle, Timothy J Benson, Mikael Hovig, Eivind |
author_facet | Clancy, Trevor Pedicini, Marco Castiglione, Filippo Santoni, Daniele Nygaard, Vegard Lavelle, Timothy J Benson, Mikael Hovig, Eivind |
author_sort | Clancy, Trevor |
collection | PubMed |
description | BACKGROUND: The immune contribution to cancer progression is complex and difficult to characterize. For example in tumors, immune gene expression is detected from the combination of normal, tumor and immune cells in the tumor microenvironment. Profiling the immune component of tumors may facilitate the characterization of the poorly understood roles immunity plays in cancer progression. However, the current approaches to analyze the immune component of a tumor rely on incomplete identification of immune factors. METHODS: To facilitate a more comprehensive approach, we created a ranked immunological relevance score for all human genes, developed using a novel strategy that combines text mining and information theory. We used this score to assign an immunological grade to gene expression profiles, and thereby quantify the immunological component of tumors. This immunological relevance score was benchmarked against existing manually curated immune resources as well as high-throughput studies. To further characterize immunological relevance for genes, the relevance score was charted against both the human interactome and cancer information, forming an expanded interactome landscape of tumor immunity. We applied this approach to expression profiles in melanomas, thus identifying and grading their immunological components, followed by identification of their associated protein interactions. RESULTS: The power of this strategy was demonstrated by the observation of early activation of the adaptive immune response and the diversity of the immune component during melanoma progression. Furthermore, the genome-wide immunological relevance score classified melanoma patient groups, whose immunological grade correlated with clinical features, such as immune phenotypes and survival. CONCLUSIONS: The assignment of a ranked immunological relevance score to all human genes extends the content of existing immune gene resources and enriches our understanding of immune involvement in complex biological networks. The application of this approach to tumor immunity represents an automated systems strategy that quantifies the immunological component in complex disease. In so doing, it stratifies patients according to their immune profiles, which may lead to effective computational prognostic and clinical guides. |
format | Text |
id | pubmed-3094196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30941962011-05-14 Immunological network signatures of cancer progression and survival Clancy, Trevor Pedicini, Marco Castiglione, Filippo Santoni, Daniele Nygaard, Vegard Lavelle, Timothy J Benson, Mikael Hovig, Eivind BMC Med Genomics Research Article BACKGROUND: The immune contribution to cancer progression is complex and difficult to characterize. For example in tumors, immune gene expression is detected from the combination of normal, tumor and immune cells in the tumor microenvironment. Profiling the immune component of tumors may facilitate the characterization of the poorly understood roles immunity plays in cancer progression. However, the current approaches to analyze the immune component of a tumor rely on incomplete identification of immune factors. METHODS: To facilitate a more comprehensive approach, we created a ranked immunological relevance score for all human genes, developed using a novel strategy that combines text mining and information theory. We used this score to assign an immunological grade to gene expression profiles, and thereby quantify the immunological component of tumors. This immunological relevance score was benchmarked against existing manually curated immune resources as well as high-throughput studies. To further characterize immunological relevance for genes, the relevance score was charted against both the human interactome and cancer information, forming an expanded interactome landscape of tumor immunity. We applied this approach to expression profiles in melanomas, thus identifying and grading their immunological components, followed by identification of their associated protein interactions. RESULTS: The power of this strategy was demonstrated by the observation of early activation of the adaptive immune response and the diversity of the immune component during melanoma progression. Furthermore, the genome-wide immunological relevance score classified melanoma patient groups, whose immunological grade correlated with clinical features, such as immune phenotypes and survival. CONCLUSIONS: The assignment of a ranked immunological relevance score to all human genes extends the content of existing immune gene resources and enriches our understanding of immune involvement in complex biological networks. The application of this approach to tumor immunity represents an automated systems strategy that quantifies the immunological component in complex disease. In so doing, it stratifies patients according to their immune profiles, which may lead to effective computational prognostic and clinical guides. BioMed Central 2011-03-31 /pmc/articles/PMC3094196/ /pubmed/21453479 http://dx.doi.org/10.1186/1755-8794-4-28 Text en Copyright ©2011 Clancy et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Clancy, Trevor Pedicini, Marco Castiglione, Filippo Santoni, Daniele Nygaard, Vegard Lavelle, Timothy J Benson, Mikael Hovig, Eivind Immunological network signatures of cancer progression and survival |
title | Immunological network signatures of cancer progression and survival |
title_full | Immunological network signatures of cancer progression and survival |
title_fullStr | Immunological network signatures of cancer progression and survival |
title_full_unstemmed | Immunological network signatures of cancer progression and survival |
title_short | Immunological network signatures of cancer progression and survival |
title_sort | immunological network signatures of cancer progression and survival |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094196/ https://www.ncbi.nlm.nih.gov/pubmed/21453479 http://dx.doi.org/10.1186/1755-8794-4-28 |
work_keys_str_mv | AT clancytrevor immunologicalnetworksignaturesofcancerprogressionandsurvival AT pedicinimarco immunologicalnetworksignaturesofcancerprogressionandsurvival AT castiglionefilippo immunologicalnetworksignaturesofcancerprogressionandsurvival AT santonidaniele immunologicalnetworksignaturesofcancerprogressionandsurvival AT nygaardvegard immunologicalnetworksignaturesofcancerprogressionandsurvival AT lavelletimothyj immunologicalnetworksignaturesofcancerprogressionandsurvival AT bensonmikael immunologicalnetworksignaturesofcancerprogressionandsurvival AT hovigeivind immunologicalnetworksignaturesofcancerprogressionandsurvival |